Celdara Medical (OnCyte)
M&A
STATUS
M&A
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
Developer of treatments in the field of immuno-oncology. The business unit has developed the most advanced autologous CAR (chimeric antigen receptor) T-Cell drug candidate uses a specific human Natural Killer cell receptor that targets tumor antigens expressed in most liquid and solid cancers.
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Office
- Lebanon, NH
- United States
Celdara Medical (OnCyte) Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Celdara Medical (OnCyte)‘s full profile, request access.
Request full access to PitchBookCeldara Medical (OnCyte) Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Celdara Medical (OnCyte)‘s full profile, request access.
Request full access to PitchBook